Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for allegedly misleading investors regarding its financial projections and business model following its spin-off from Labcorp [1][3][4]. Company Overview - Fortrea is a global clinical research organization (CRO) that assists in the development of pharmaceutical and medical device products. It was spun off from Labcorp in June 2023 and had ongoing long-term projects at that time [3]. Allegations of Misleading Information - The lawsuit claims that Fortrea overestimated the revenue from its Pre-Spin Projects for 2025, overstated cost savings from phasing out transition service agreements (TSAs), and inflated its EBITDA targets for 2025, presenting an overly optimistic view of its post-spin-off business model [5]. Market Reactions and Stock Performance - On September 25, 2024, Jefferies downgraded Fortrea from Buy to Hold, citing weaknesses in the CRO model and a lack of real cost savings, leading to a stock drop of over 12% [5]. - Following the abrupt cancellation of two conferences, Baird Equity Research downgraded Fortrea to Neutral on December 6, 2024, resulting in an additional stock decline of 8% [5]. - On March 3, 2025, Fortrea reported disappointing Q4 and full-year 2024 results, admitting that its revenue and EBITDA goals for 2025 were unrealistic, causing the stock to drop more than 25% [5].

Core Viewpoint - The market anticipates Medpace (MEDP) will report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended June 2025 [1][3]. Earnings Expectations - The consensus EPS estimate for Medpace is $3.00 per share, reflecting a year-over-year increase of +9.1% [3]. - Expected revenues for the quarter are $541.19 million, which is a 2.5% increase from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 0.81%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Medpace is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.91%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with positive readings being more reliable [9][10]. - Medpace currently holds a Zacks Rank of 3, which complicates the prediction of an earnings beat given the negative Earnings ESP [12]. Historical Performance - In the last reported quarter, Medpace exceeded the expected earnings of $3.06 per share by delivering $3.67, resulting in a surprise of +19.93% [13]. - The company has successfully beaten consensus EPS estimates in the last four quarters [14]. Conclusion - While Medpace does not appear to be a strong candidate for an earnings beat based on current estimates, investors should consider other factors before making investment decisions [17].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fortrea Holdings Inc. regarding a class action lawsuit due to alleged misleading statements and overestimations related to the company's financial projections and business model [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from July 3, 2023, to February 28, 2025 [3]. - Allegations include that Fortrea overestimated revenue contributions from long-term projects, overstated cost savings from exiting transition services agreements, and inflated EBITDA targets for 2025 [3]. Allegations Breakdown - Fortrea allegedly overestimated the revenue from its Pre-Spin Projects for 2025 [3]. - The company is accused of overstating potential cost savings from exiting certain agreements [3]. - As a result, the company's previously announced EBITDA targets for 2025 were inflated [3]. - The viability of Fortrea's post-spin-off business model and its financial prospects were also allegedly overstated [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 1, 2025, to participate in potential recovery [4]. - Registered shareholders will receive updates through a portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/psl ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=154294&from=3 CLASS PERIOD: Ju ...

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=153678&from=3 CLASS PERIOD: Ju ...

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Company Overview - Fortrea is a global clinical research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [2]. - The company was spun off from Labcorp in June 2023, with ongoing long-term projects at the time of the spin-off [2]. Allegations of the Lawsuit - The lawsuit claims that Fortrea overestimated revenue contributions from pre-spin projects, overstated cost savings from exiting transition services agreements (TSAs), and inflated its EBITDA targets for 2025 [3]. - Specific allegations include: - Overestimation of revenue from pre-spin projects [3]. - Overstatement of cost savings from exiting TSAs [3]. - Inflated EBITDA targets for 2025 [3]. - Overstated viability of Fortrea's post-spin business model [3]. Impact of Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and a lack of material cost savings from exiting TSAs, leading to a stock price drop of over 12% [4]. - On December 6, 2024, Baird Equity Research downgraded Fortrea to neutral, resulting in an 8% decline in stock price after the company canceled two scheduled conferences [5]. Financial Performance Disclosure - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, revealing that pre-spin projects were underperforming and negatively impacting financial performance [6]. - Following this announcement, Fortrea's stock price fell by more than 25% [6].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Company Overview - Fortrea Holdings Inc. is a global clinical research organization (CRO) that provides biopharmaceutical product and medical device development solutions to various customers [2]. - The company was spun off from Labcorp Holdings Inc. in June 2023, with ongoing long-term projects at the time of the spin-off [2]. Allegations of the Lawsuit - The lawsuit alleges that Fortrea overestimated revenue contributions from pre-spin projects, overstated cost savings from exiting transition services agreements (TSAs), and inflated its EBITDA targets for 2025 [3]. - Specific claims include that Fortrea's business model viability and financial prospects were overstated, leading to significant stock price declines following negative reports from analysts [3][4][5]. Stock Performance and Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model, resulting in a stock price drop of over 12% [4]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral from outperform on December 6, 2024, leading to an additional stock price decline of over 8% [5]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, causing a stock price drop of more than 25% [6]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Fortrea securities during the class period to seek appointment as lead plaintiff in the lawsuit [7]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [8].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Company Overview - Fortrea is a global clinical research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [2]. - The company was spun off from Labcorp in June 2023, with ongoing long-term projects at the time of the spin-off [2]. Allegations of the Lawsuit - The lawsuit claims that Fortrea overestimated revenue contributions from pre-spin projects and overstated cost savings from exiting transition services agreements (TSAs) [3]. - It is alleged that Fortrea's EBITDA targets for 2025 were inflated, leading to an overstatement of the company's business viability and financial prospects [3]. Impact of Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and a lack of material cost savings from exiting TSAs, resulting in a stock price drop of over 12% [4]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral from outperform on December 6, 2024, leading to an 8% decline in stock price [5]. Financial Performance Disclosure - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, revealing that pre-spin projects were underperforming [6]. - The announcement led to a significant stock price drop of over 25% [6].

SAN DIEGO, June 9, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fortrea Holdings Inc. (NASDAQ: FTRE) securities between July 3, 2023 and February 28, 2025, both dates inclusive (the "Class Period"), have until August 1, 2025 to seek appointment as lead plaintiff of the Fortrea class action lawsuit.  Captioned Deslande v. Fortrea Holdings Inc., No. 25-cv-04630 (S.D.N.Y.), the Fortrea class action lawsuit charges Fortrea and certain of Fortrea's top executive ...